Lung Cancer News and Research

Latest Lung Cancer News and Research

Progression to combined pituitary hormone deficiency common in IGHD

Researchers have found that a high proportion of children initially diagnosed with isolated growth hormone deficiency will progress to combined pituitary hormone deficiency.

22 Dec 2014

Growth hormone boosts muscle development in Prader-Willi syndrome

Randomised trial findings show a positive effect of growth hormone therapy on muscle thickness in infants with Prader-Willi syndrome.

22 Dec 2014

Two hormones better than one for hypoglycaemia prevention with artificial pancreas

Artificial pancreas systems significantly improve glycaemic control in adolescents and adults with Type 1 diabetes, shows a head-to-head trial of single- and dual-hormone systems versus a conventional insulin pump.

22 Dec 2014

‘Positive’ report of growth hormone in idiopathic short stature

US researchers report “positive” experiences with growth hormone therapy in children with idiopathic short stature.

22 Dec 2014

UT Southwestern researchers find new potential target for halting tumor growth

UT Southwestern Medical Center researchers have discovered that brain tumors are capable of burning acetate for fuel, providing a new potential target for halting tumor growth.

19 Dec 2014

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests.

18 Dec 2014

U-M researchers devise reliable way to grow tumor cells

In a development that could lead to a deeper understanding of cancer and better early-stage treatment of the disease, University of Michigan researchers have devised a reliable way to grow a certain type of cancer cells from patients outside the body for study.

18 Dec 2014

Survey highlights need for increased public education on benefits of lung cancer screening in France

A prospective nationwide survey on perceptions of lung cancer in the general population of France highlights a need for increased public education on the benefits of lung cancer screening, the good survival rates of early-stage disease and the improved outcomes with new therapeutic strategies, including targeted-therapies.

18 Dec 2014

University Hospital Bonn to validate accuracy of VolitionRx’s Nucleosomics technology in lung cancer

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the University Hospital Bonn in Germany will initiate a clinical confirmatory study to assess VolitionRx’s proprietary Nucleosomics platform technology for the diagnosis of lung cancer through a blood test in individuals.

18 Dec 2014

Postop chemotherapy supported for stage III NSCLC

Study findings challenge the belief that preoperative chemotherapy is superior to postoperative chemotherapy for patients with clinical stage III non-small-cell lung cancer.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Lung cancer in women: an interview with Harold Wimmer and Chuck Brynelsen

We at the American Lung Association know that lung cancer is the number one cancer killer among women, however, there is a startling lack of information available to the public regarding lung cancer.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

New holistic approach to cancer treatment

The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center.

15 Dec 2014

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

From Evident Corporation - Life Sciences 15 Dec 2014